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Article 1

SYMPOSIUM
ENGINEERING EDEN:
INVESTIGATING THE LEGAL AND

ETHICAL DILEMMAS OF
MODERN BIOTECHNOLOGY

BIOTECHNOLOGY:
CUI BONO, A UTEM CUI MALO?'
DR. JOLYON JESTY*

Thank you very much. It is an honor, yet also scary, to be
here.
Teaching bioethics to medical students, and now to
undergraduates, has been my hobby for about fifteen years.

Professor of Medicine, Stony Brook University. These remarks are an actual
transcript of the author's comments at the St. John's Journal of Legal Commentary
Symposium on Feb. 25, 2005
1 Translating as 'To whom the benefit; but to whom the harm?' For a translation of the
individual parts of the phrase, see Latin Phrases, http://www.angelfire.comlempire/
martiana/gens/LatinPhrases.html (last visited Nov. 7, 2005). The slides that accompanied
this presentation are available as a PDF file by e-mail request to the author
(jolyon.jesty@sunysb.edu), or directly at http://ms.cc.sunysb.edu/-jjesty/sjjlc.pdf (last
visited Nov. 7, 2005).
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Thus, I think I have a good background, but I am pretty
unqualified compared to the upcoming speakers. I think that my
purpose here is to introduce the subject of "Engineering Eden," so
I will begin the Symposium with a background discussion. I also
want to raise some questions for you as I go along, and I expect,
judging by the titles and backgrounds of the following speakers,
that some of those questions may be answered by lunchtime.
The first thing to address is, "Who are bioethicists?" Wesley
Smith pointed out the irony that even a hairdresser needs a
license. 2 Bioethicists do not need licenses; in fact they can be
complete amateurs, like me. Maybe there is a new program for
St. John's here: Masters in Bioethics.
"Engineering Eden." Let us think about what this phrase
means. I am a blood clotting person; it's my business. We blood
clotting people, by the way, kill a lot of people in western
countries. Although deaths from heart disease and stroke have
fallen substantially in recent years, clotting problems of various
sorts - chiefly heart attacks and strokes - still account for about

forty percent of deaths in the United States. 3
We also have experience of other serious diseases, and some
are directly relevant to the perverse ethics of the American
health system. Hemophilia A, for example, affects between one
in five thousand and one in ten thousand males worldwide. 4 For
the most seriously afflicted, this disease was uniformly fatal until
about the 1960's. 5 Even now hemophilia causes major life-long
problems, and is extremely expensive to treat. Adults with
severe hemophilia will spend about two hundred thousand
dollars per year on treatment if they want to have a functioning

2 See WESLEY J. SMITH, CULTURE OF DEATH: THE ASSAULT ON MEDICAL ETHICS IN
AMERICA, at x (Encounter Books, 2000); Sheryl Gay Stolberg, Bioethicists Find
Themselves the Ones Being Scrutinized, N.Y. TIMES, Aug. 2, 2001, at Al.
3 See Robert N. Anderson & Betty Smith, Deaths: Leading Causes for 2002, NATIONAL
VITAL STATISTICS REPORTS (Mar. 7, 2005), available at http://www.cdc.gov/nchs/data/nvsrl
nvsr53/nvsr5317.pdf, 13-14 (stating that 29% of adult deaths in United States were
caused by heart disease, and 7% from stroke). See generally Blood Clots, http://www.
drkoop.com/ency/93/001124.html (last visited Sept. 19, 2005) (describing blood clots as
"clumps that result from coagulation of the blood").
4 See Medline Plus, http://www.nlm.nih.gov/medlineplus/ency/article/000538.htm (last
visited Sept. 19, 2005) (stating that Hemophilia A affects one in 5,000 men).
5 See What is a Bleeding Disorder?, http://www.hemophilia.orgfbdi/bdi_ history.htm
(last visited Sept. 19, 2005) (articulating that discovery of clotting factors in 1960's led to
saving of lives of hemophiliacs).

20051

CUIBONO,AUTEM CUIMALO?

lifestyle. 6 I am not talking about playing rugby; I am talking
about getting up in the morning and going to work. Such
treatment is far beyond the means of either individuals or most
companies who might employ them. If a severe hemophiliac is
insured in a small American company, they are liable to be fired
because the insurance premiums of that company will get beyond
the means of the people who run it.
Now I am going to go through some brief definitions. DNA, of
course, is very much what we are going to talk about today. DNA
is your history and your future. Recombinant DNA means taking
a foreign gene, and inserting it into some other DNA. For
instance, we might take an insecticidal gene from bacteria and
insert it into maize (corn). That is recombination. For example,
the human insulin gene is now expressed in bacteria in very
large amounts, and all insulin for diabetic treatment comes out of
a bacterium. It is a much better treatment than the old insulin,
actually, which was pig insulin.
My second example of
recombinant DNA highlights some mistakes and dangers.
Interleukin 4 is a mammalian protein, but if we insert the gene
into the Mouse Pox virus, which is very closely related to Small
Pox, we get an extraordinarily virulent version of Mouse Pox.
This is really frightening. It was discovered by mistake in
Australia a few years ago, and it was published. 7 We must
ponder whether such results should have been published. The
publication is a detailed recipe for making something really
dangerous and closely related to Small Pox.
What about some transgenic humans?
What about a
basketball gene? How about a height gene, also known as a
growth hormone gene? More dunking. What about a cycling
gene - more hemoglobin, so you can win the Tour de France
seven years in a row? Or what about a TV presenter gene - more
big hair? However, those examples are essentially facetious: let's
start to consider the treatment of real disease.
6 See Washington Days 2004 Position Paper: Access to Health Insurance (2004),
available at http://www.hemophilia.org/events/washingtonday-positionpapers-hi.htm
(quoting yearly cost estimates for treatment ranging from $150,000 to $300,000 per year
excluding complications).
7 See Ronald J. Jackson et al., Expression of Mouse Interleukin-4 by a Recombinant
Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic
Resistance to Mousepox, 75 J. OF VIROLOGY 3, 1205, 1205-10 (Feb. 2001), available at
http://www.pubmedcentral.nih.gov/article render.fcgi?artid= 114026 (discussing effects of
modifying one virus).
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First, we have the embryo stage. Imagine we have an embryo
we would like to improve with a new gene. If we insert a gene
into the early embryo, or into the egg it was formed from, that
inserted gene will go into every cell of the organism, including
the germ line cells, which will produce the eggs and the sperm of
that organism in the future.
The other name for that is
"transgenic," and once the inserted gene is in the germ line cells,
it is out in the big, wide world, if it is allowed to get out.
The other sort of introduction of DNA is more localized, and it
goes into somatic cells. This is "gene therapy." That word
"somatic" means any cell in your body except for eggs or sperm.
Therefore, the somatic cells are not reproductive cells. They are
regular body cells: liver, bone, and muscle, et cetera. So, when we
insert a cell into somatic cells, as opposed to germ line cells, we
are ensuring that the inserted cell is not going into future
generations. In practice, gene therapy has come nowhere near
being stable enough for one treatment even to last one
generation.
Another term we need to think about is "clones." We are able to
clone mice very easily now. There are many other clones, which
we may define as organisms with identical DNA. Most bacteria
are like that because they multiply by dividing. All we do is split
the cell in half, and we now have two new cells. Some plants
reproduce that way normally, and some human clones exist as
well. For example, here are my identical twin daughters, about
twenty years ago. They have identical DNA, but they underline
the difference between simpler organisms and humans: they are
completely different people. So, even though we might be able to
control DNA exactly in the future, we do not necessarily know
what we are going to get - as I myself know very well. My
daughters are very nice people, but very different.
Now, let us go into games we can play with DNA and the genes
within it; and I want to point out that this is not at all new. Old
DNA engineering has been going on for a while: breeding. True
breeding started around eight or ten thousand B.C.s when people
started forming small villages. They surely realized it was easier
8 Cf. Zach Zorich, Origins of Farming Unearthed, DISCOVER, Jan. 2005, at 13
(describing new anthropological finds that disturb settled principles that human breeding
of farm animals began 11,000 years ago, and dating farming and breeding to 23,000 years
ago).
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to grow food and harvest it, and easier to control animals rather
than run around the countryside trying to hunt them. From that
date on, breeding has been the chief means of selection of traits.
Breeding can be almost as powerful in the end as the modern
methods, but limited for two reasons. Number one, breeding is
very slow; and number two, the selection of the possible traits
that you might want is really quite small. You cannot pick a
gene out of a totally foreign species by breeding. You can only
breed within a species, but I have one slide here to emphasize
what sort of variation you can still get. Here are a Clydesdale
and a Shetland pony. You can get much more spectacular
breeding variation in dogs, of course, all the way from a
Chihuahua to a Newfoundland, or in maize. Most of you
probably know that maize started off in Mexico as a wild plant
that bears almost no visible relation to the present varieties of
corn.
Now, let us talk about therapies - because the whole purpose
of this new "Eden" that this conference is about is the idea of
making things better. Eden is supposed to be perfection, so I
want to talk briefly about the earliest examples of therapeutics.
Folk wisdom has circulated for thousands of years. In fact, in ten
minute's time, I will discuss a drug that has been known for
several hundred years to be an effective treatment of a major
disease. Folk wisdom is useful, but much of it is non-specific, and
unproven. You go out to the so-called health food store, and you
pick a bottle of whatever off the shelf, and often you just have to
have faith that the bottled treatment is going to help you. Faith
is actually pretty effective; in scientific terms, and this is called a
placebo effect. Even if the compound does nothing, it is probably
going to improve forty percent of the people who buy it.
I pick arbitrarily on 1747 as the first beautiful piece of science
that I know of. The date might be slightly wrong. James Lind
worked for the British Navy, went on a voyage or two, divided
the crews into clearly defined groups, and fed those groups
different things. 9 The group of crewmen who almost instantly got
their scurvy cured were the ones with lemons or limes in their

9 See Historic Figures: James Lind (1716-1794), http://www.bbc.co.ukthistory/
historic figuresflindjames.shtml (last visited Sept. 19, 2005) (relating historical account
of Lind's life and his contributions to curing scurvy).
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diet, and that is why people like me who talk funny are called
"limeys."
Very soon after, in 1774, we have the development of the small
pox vaccine. This started with a theory that had been known for
many hundreds of years: that Cow Pox protected against Small
Pox.10 Everybody knew that milk maids had beautiful
complexions, and that is where the notion began. The milk
maids were always exposed to Cow Pox, and hence, they did not
get Small Pox - and they were gorgeous. You may think I have
got the wrong date, but actually 1774 is correct. This specific
introduction of Cow Pox was done from a cow, and it was done
not by Jenner, but by the brother of my great-great-great-great
grandfather, a farmer. It is well-documented. If you want to
look it up, research Benjamin Jesty. I will read his gravestone,
because it is a little difficult to read. "He was born at Yetminster
in this county." [Dorset, where Thomas Hardy was also from.]
"He was an upright honest man." Of course. He was a Jesty,
right?] "Particularly noted for having been the first person
known to introduce the Cow Pox by inoculation, and who, from
his great strength of mind, made the experiment from the cow on
his wife and two sons." There is an ethical question for you: he
didn't inoculate himself; but then he had already had Cow Pox.
There was a paper in Lancet in December, 2003, about
Benjamin's work.l But injecting his own wife and two sons there is another important ethical question for you. The younger
son was only two years old. Benjamin Jesty stuck a needle into a
pock on the cow's udder, and did the inoculation similarly to the
way vaccination is done: a scratch on the arm. His wife got very
sick from his actions but all three survived. The two sons were
later challenged with Small Pox, meaning that someone
deliberately tried to infect them with Small Pox. His portrait
was painted by the Vaccine Pock Institute, so he did have some
official recognition.

10 See Alfred J. Sciarrino, The Grapes of Wrath, Part II, 8 MICH. ST. J. MED. & L. 1,
10-13 (2004) (discussing Dr. Edward Jenner's discovery of cow pox as an effective
vaccination for Smallpox).
11 See Patrick J. Pead, Benjamin Jesty: New Light in the Dawn of Vaccination, 362
LANCET 2104, 2104-09 (2003) (explaining experiments of Benjamin Jesty and recognizing
him as the "first vaccinator").
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So much for DNA and biology.. .what about engineering? John
Snow, the father of epidemiology,1 2 is, to my mind, the first
bioengineer, but it is old-fashioned mechanical engineering. He
was the first one to identify the water supply as being the source
of cholera. John Snow and Benjamin Jesty together show that
bioengineering is not all new magic; instead, it has been going on
for some time. However, we must note that these examples are
not part of this new "Engineered Eden."
Now, coming to modern times, we need to discuss 1953.
Watson and Crick were not the people who proved DNA is the
hereditary material; that was done in 1944 by a group led by
Oswald Avery.13 Just seven years after that, Watson and Crick
worked out the structure of DNA, and the structure was key to
understanding how it works. This is because DNA and its
structure include a means of copying DNA very faithfully.14 The
DNA copying mechanism in eukaryotes, which is the upper life
form of organisms with nuclei in their cells, is accurate to about
one part in a hundred million. So, one base copying, roughly, will
go wrong in every hundred million; this is extraordinarily
accurate, particularly for a living thing. (The mistakes, of course,
are what we call mutations, and are a fundamental part of the
theory of natural selection.)
After Watson and Crick's discovery in 1953, the discoveries in
the field of DNA came rapidly. The DNA code of base triplets
was cracked in the 1960's.
DNA was transferred between
different organisms in the early 1970's; Paul Berg was the first to
do that.15 Berg then called his moratorium, and brought together
a national group to decide on rules and regulations about
12 See Richard W. Clapp & David Ozonoff, Environment & Health: Vital Intersection
of Contested Territory?, 30 AM. J. L. AND MED. 189, 189-90 (2004) (noting that origins of
epidemiology are generally traced to Dr. John Snow and his water supply research).
13 See Dr. jur. Sandra Schmieder, Scope of Biotechnology Inventions in the United
States and in Europe - Compulsory Licensing, Experimental Use and Arbitration:A Study

of Patentabilityof DNA-Related Inventions with Special Emphasis on the Establishment of
an Arbitration Based Compulsory Licensing System, 21 SANTA CLARA COMPUTER & HIGH

TECH. L.J. 163, 167 (2004) (positing Oswald T. Avery's discovery of DNA's purpose as the
"cornerstone for further ground-breaking inventions in biotechnology").
14 See David C. Hoffman, Note, A Modest Proposal: Toward Improved Access to
Biotechnology Research Tools by Implementing a Broad Experimental Use Exception, 89
CORNELL L. REV. 993, 994 (2004) (indicating James Watson's and Francis Crick's solving
of DNA's double helix structure "fundamentally transformed modern biology").
15 See Terri A. Jones, Note, PatentingTransgenic Animals: When the Cat's Away, the
Mice Will Play, 17 VT. L. REV. 875, 879 (1993) (denoting Paul Berg's creation of
recombinant DNA as launching point for modern genetic engineering).
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recombinant DNA work. But just a few years later, in 1977, a
human protein was produced in a bacterium: somatostatin.
Then we get to the crucial year of 1978. Louise Brown was the
first test tube baby, using in-vitro fertilization techniques
developed by Steptoe and Edwards.16 Yet, at that time, no one
even raised the question about all the spare, unused, human
embryos created via in-vitro fertilization. I do not know why. Of
course, now those questions are being raised, but for some reason
they were not raised then, and the quandary about what to do
with them, or whether they may be "used", is still very much
with us.
And now let's consider what this conference is really about "Engineering Eden," referring to gene therapy, i.e. the
introduction of a gene into a human (usually a functioning gene
to replace a defective one). In 1990, the first gene therapy trial
was performed on a child with a very simple immune disorder;
the child lacked just one enzyme coded by one gene.1 7 That is the
simplest situation that you can attack with gene therapy, with
only one gene copy in your DNA. Furthermore, this child lacked
the enzyme called adenosine deaminase; and with this particular
enzyme, it does not matter whether the enzyme is expressed at
high or low levels, as long as you have some. This means that
there were no problems about controlling how much enzyme was
expressed.
In the same year, 1990, as that first gene therapy trial for the
child lacking the enzyme, we had the first transgenic cow. Now,
this is in the germ line. We are talking about cows, or, more
specifically, a race of cows that can produce a human protein in
their milk. That is a very effective way of making recombinant
protein; and with regard to the ethics and the risk, it is fortunate
that cows weigh quite a lot, and they do not tend to trot around
the countryside very much and get out. Therefore, we do not
have to really worry much about those genes getting out into the
wild cow population because there are no wild cows left anyway
these days.
16 See The Moral CaseAgainst Cloning for Biomedical Research, 18 ISSUES L. & MED.
261, 267 (2003) (attributing birth of test-tube baby Louise Brown to Dr. Patrick Steptoe
and Dr. Robert Edwards).
17 See Wilder J. Leavitt, Note, Regulating Human Gene Therapy: Legislative
Overreaction to Human Subject Protection Failures,53 ADMIN. L. REV. 315, 321-22 (2001)
(explaining first gene therapy trial, performed in 1990).
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But what about genes that can get out into the wild world? In
1992, we have a worrying event - well, to me, it is worrying. You
do get a few personal opinions in this point. The FDA18 decided
that transgenic food is not inherently dangerous. 19 However, the
FDA made a very narrow statement referring to lack of any
direct toxic effects to humans from eating food made from
transgenic animals or produce. So, if you eat transgenic corn,
which you probably do, or if you eat transgenic tomatoes, which
you almost certainly do these days, you are not going to get sick
from eating those crops. What the FDA did not address - and
what the FDA has no authority to address - is whether those
transgenic genes might get out into the wild population and what
damage that might do. Mexico, in particular, is extremely
worried about the genes in Monsanto's herbicide-resistant maize,
because that transgenic corn has already got down to Mexico, its
"transgenes" mixing with the wild, earlier population of maize.
In 1997, scientists in Scotland cloned Dolly,
Moving on ....
the sheep. There were many failures involved in that experiment,
and there were many failures before Dolly was born. Moving on
further towards the present, in the year 2000, researchers
completed the draft sequence of the human genome. That is your
entire DNA sequence; however, for a lot of that sequence, the
function is not described.
In 2001, we come to probably the first problem of "Engineering
Eden." Well, maybe the transgenic crop problem was the first
problem, but the year 2001 is the date of the first human
problem. Ten French children with an immune disease, where
each lacked one specific protein, which was actually different
from the one I just talked about, were initially cured by gene
therapy using a virus vector. (Vector: the virus, complete with an
inserted copy of the human gene and other pieces of DNA that
control its expression, carries the gene into the body's cells.)
Later, two of the ten children got leukemia caused by the virus
vector. These were retro-viruses, and they are a rather nasty
type of virus. They tend to plop down in DNA where they are not
18 U.S. Food and Drug Administration, http://www.fda.gov/ (last visited Sept. 19,
2005).
19 See John Charles Kunich, Mother Frankenstein, Doctor Nature, and the
Environmental Law of Genetic Engineering, 74 S. CAL. L. REV. 807, 843 (2001) (explicating
FDA's position on safety of genetically modified foods).
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wanted, and turn on cancer-causing genes. That means cell
growth goes out of control - which is what leukemia and other
cancers are. So, that was the first - but it certainly will not be
the last - instance of gene therapy gone awry.
In 2001, and I think this is the end of my history list, we have
the first deliberate production of human embryos not for
reproduction. A private in-vitro fertilization center in Virginia
made human embryos specifically for destruction.20 These
embryos were not created for implantation into women to make
babies. The purpose of that mixing of egg and sperm was to
make human embryonic stem cells, and the purpose of that was
to start playing around with human embryonic material in the
lab. These acts were perfectly legal both in Virginia and in the
United States then, and they are still legal today in 2005.21
Brave New World, 2001, with the first deliberate destruction of
human embryos for scientific purposes.
Now, what about regulations? Having discussed the history of
"Engineering Eden," let us talk about the regulations involved. I
hope you will get the idea that regulations, in the United States
in particular, are an absolute mess. In the 1970's, Paul Berg
looked at the risks involved in recombinant DNA in bacteria; but
there was no problem there, and people work with that all of the
time, and it is perfectly safe. But in the 1970's, there were
absolutely no regulations about generation of human embryos.
In the 1980's, there were no regulations about transgenic crops
or animals until they become food - until you pop them into your
mouth. So, for instance, I read in the paper just recently that
you will very soon be able to buy fluorescent zebra fish in pet
stores; that fluorescent gene is now permanently into the germ
line of these modified zebra fish, and zebra fish multiply like
crazy. So you can expect that the wild population of zebra fish is
20 See Sina A. Muscati, Defining a New Ethical Standard for Human In Vitro
Embryos in the Context of Stem Cell Research, 2002 DUKE L. & TECH. REV. 26, 34 (2002)
(noting how Jones Institute for Reproductive Medicine at the Eastern Virginia Medical
School was first to produce human embryos solely in order to harvest stem cells).
21 See VA. CODE ANN. § 2.2-2233.2 (West 2005) (prohibiting use of funds from the
State Biotechnology Commercialization Loan Fund for human embryonic stem cell
research but not prohibiting private funding of such research); Steven Goldberg, Cloning
Matters: How Lawrence v. Texas Protects TherapeuticResearch, 4 YALE J. HEALTH POL'Y
L. & ETHICS 305, 313 (2004) (emphasizing that President Bush's 2001 prohibition on
using federal funds for embryonic research permits such research to continue, so long as it
is privately funded).
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going to include some fluorescent ones pretty soon. There were
no regulations about that, either, and that is still true.
Now, many of my students, my undergrads in particular, think
that President Bush banned work on embryonic stem cells. He
did not. Working on embryonic stem cells is still perfectly legal
in the United States; however, Bush did ban the use of federal
funds for such research. 2 2 This might be called a wrong-headed
decision, because there are still no regulations about other people
who are not using federal money performing research on human
embryonic stem cells. Furthermore, there is still no federal law
against reproductive cloning, which means the production of
cloned embryos for implantation and birth. Such embryos can be
genetically modified before implantation into a uterus and the
23
development of a baby, and that is still legal.
In 2004, human embryos were finally cloned by Dr. Hwang in
Korea and were implantable at that stage. He could have started
trying to modify the embryos, and he could have implanted them
in utero. Mind you, he had to go through about two hundred and
eighty human eggs from volunteer women, who had donated
their eggs, to get just a handful of cloned embryos. However,
regardless of the low success rate, this shows that the possibility
is right there. There is absolutely nothing to stop me settling in
any number of states in the United States - a majority of states,
actually - and cloning human embryos. Somebody gives me some
money, and then I can find a source of discarded embryos from
IVF centers where I can start cloning. Nobody can take me to
court for that yet.
I think there is a better way, and Britain is an example. Back
in 1991, fifteen years ago, way before Dolly, the British
government decided to form a formal authority, called the
Human Fertilization and Embryology Authority. 24
22 See Goldberg, supra note 21, at 313 (highlighting said prohibition permits such
research to continue "so long as" it is privately funded) (emphasis added).
23 Although many bills have been introduced in Congress that include such a ban,
none has reached the President's desk. In contrast, a number of States, about ten in 2005,
not including New York, have bans on reproductive cloning. See National Conference of
State Legislatures, State Human Cloning Laws (June 21, 2005), http://www.ncsl.org/
programsfhealthlgenetics/rt-shcl.htm.
24 See Human Fertilization and Embryology Authority, http://www.hfea.gov.uk/Home
(last visited Sept.19, 2005) (describing itself as "a non-departmental Government body
that regulates and inspects all UK clinics providing IVF, donor insemination or storage of
eggs, sperm or embryos").
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Despite Britain having a highly regulated environment, stem
cell research in Britain is much further advanced than in the
United States. Everybody knows the rules; the rules are quite
clear. You are allowed to do this and that, with authorization,
but you are not allowed to do reproductive cloning. A large
majority of British people are pleased about embryonic-stem-cell
research for therapeutic purposes, and they are also pleased
about their country's effective regulations.
From the problems of regulating embryos and cloning, let me
move on to drug regulation and some of its ethical problems. The
FDA requires that drugs be safe, 25 whatever that means. Drugs
must also be effective. But what does "effective" mean? It means
generally that the new drug must be more effective than nothing.
That second requirement is a serious problem because it means
that neither patients nor doctors can really compare drugs with
each other, since the trial process for drugs involves comparing a
drug with a placebo. 26 The fact is that manufacturers are not
expected to compare their product with an existing product. Only
when something major happens do comparisons between existing
drug products get done, and then usually by the government.
The hypertension market, for example, is a fifteen-billion-dollar
drug market. 2 7 The majority of that money buys fancy, newer
drugs. I will not tell you the details, but they are just ordinary
stuff that your doctor is going to prescribe for you. However, for
just one patient these drugs are going to cost you or your
insurance company about three to five hundred dollars a year. In
2002 the NIH2S funded a study to compare these new expensive
classes of hypertension drugs with the old, cheaper, treatment of
water pills, i.e. diuretics. NIH found that diuretics are more
25 See 21 U.S.C.S. § 355(d) (Law. Co-Op. 2005) (empowering FDA to refuse a new
drug application if drug is found unsafe for use).
26 See 21 C.F.R. § 314.126(b)(2)(i) (2005) (describing characteristics of an adequate
and well-controlled study that supports effectiveness of a new drug as including a placebocontrolled element).
27 See generally Medicure Announces First Quarter Financial Results, CAN. CORP.
NEWSWIRE, Oct. 14, 2004 (noting "[tihe cardiovascular market is the largest
pharmaceutical sector with annual global sales of over US $70 billion").
28 See Scott Davison, Article, Influencing NIH Policy over Embryonic Stem-Cell
Research: An Administrative Tug-of-War between Congress and the President, 22 J.
NAALJ 405, 409 (2002) (explaining that National Institutes of Health is an
administrative agency within Department of Health and Human Services that "creates
standards for organizations to obtain federal funding for many types of biomedical
research").
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effective than all or any of the new drug classes in controlling
hypertension. So, all those new drugs were licensed because they
are better than nothing. They were not compared with the old,
previous treatments until the NIH spent a lot of money on this
study. And still doctors prescribe the new expensive ones.
Such studies also bring up a thorny ethical question. If a
treatment exists, and you develop a new drug, then you do a trial
on patients. If I am a patient in the control group receiving a
placebo, I am then getting treatment which is poorer than the
current standard or available treatment. That came out a little
confused, but I hope you get the message. So, where there is an
existing treatment, is it right to do your standard drug trial
where the control group is actually getting treated with nothing?
I am not going to answer that question. Think about it.
The next question we must address, is "Who are drug
consumers?" Doctors write prescriptions. Most consumers either
do not pay at all, or pay a flat deductible. Occasionally, there will
be consumers who actually have to pay cash for their drugs, but
still it is the doctor deciding. Until recently, that included people
on Medicare, but they are not in the majority. None of those
people, neither the doctors nor the majority of patients, have an
interest in the price of that drug. So, insurance companies
actually pay the cost.
To illustrate my point, let us examine advertisements from a
recent New York Times. 29 These ads, actually, happen to be fullpage ads right opposite each other. The left-hand one is a
standard ad for a T-Mobile® phone service, and the right-hand
one is what I call a "hard on" prescription pill for erectile
dysfunction. There is a disconnect between these two ads. The
advertisement on the left is an ordinary ad: it is all about cost
and value.
The advertisement on the right has absolutely
nothing about cost in it.
Imagine being able to advertise
something with no information about cost. It tells you that the
market for that product, Cialis®, is so totally screwed up that the
consumers have no interest in cost. I am not sure how to fix this
problem. I just wonder who benefits.
29 See generally Simon King, Eli Lilly Launches Bullish Marketing Campaign for ED
Treatment Cialis,WORLD MARKETS ANAL., July 13, 2004 (noting full page advertisements
in major news publications supporting "Cialis Promise" campaign).
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For my final point, I want to tell you a tale of two drugs. The
left-hand drug is difficult to make, and is a rare natural product.
It came from folk wisdom, as I referred to earlier, known for
hundreds of years, although the structure of the drug was not
known until recently.
The advertising budget is nothing.
Certain drug companies were interested in this drug for some
time, but decided it was not in their financial interest, despite
there being five hundred million people in the world infected
with a disease that this drug treats, and very effectively too.
There are between one and two million deaths per year from that
disease, mostly children.
Now, for the other drug, have a look at the right. This
prescription drug is easy and cheap to make. The advertising
budget in the United States is more than a hundred million
dollars per year, and the revenue is approximately one billion per
year. That figure was from last year, so by now the revenue is
probably about $1.2 billion. As far as medical benefits go, this
drug has saved no lives; the benefit is mainly emotional.
So what are these in my tale of two drugs? The first drug I
described, the one on the left, as you probably guessed, is a
malaria drug, called Artemisinin, derived from a Chinese shrub.
The drug on the right is Viagra.
Thank you very much.

